Xcell Biosciences Announces Joint Research Collaboration with Thermo Fisher Scientific to Advance the Next Gen Cell Therapies

Xcell Biosciences, one of Dynamk Capital’s standout portfolio companies and Thermo Fisher are working together to supercharge regulatory T cell (Treg) and tumor-infiltrating lymphocyte (TIL) therapies—next-gen treatments designed to tackle autoimmune diseases and solid tumors, which account for roughly 90% of adult cancers

Why it matters:

·      Builds on Xcell’s AVATAR™ platform to enhance manufacturing scalability, reproducibility, and safety in cell therapy production

·      Leverages Thermo Fisher’s proven tools to streamline modular, closed-loop manufacturing workflows

·      Establishes collaboration with Themo Fisher, a key strategic player